# Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

> **NCT03410030** · PHASE1,PHASE2 · COMPLETED · sponsor: **HonorHealth Research Institute** · enrollment: 27 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreas Cancer
- Pancreatic Adenocarcinoma Resectable
- Pancreatic Ductal Adenocarcinoma
- Pancreas Metastases

## Interventions

- **DRUG:** Ascorbic Acid
- **DRUG:** Paclitaxel protein-bound
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03410030
- **Lead sponsor:** HonorHealth Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2021-09-14
- **Final completion:** 2022-01-10
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410030, "Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03410030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*